RemeGen (HKG:9995, SHA:688331) said it invested in various wealth management products offered by Huatai Securities, according to a Friday filing with the Hong Kong bourse.
The biopharmaceutical company invested 60 million yuan in a fixed-income product that invests in debt assets, 75 million yuan in another fixed-income product that covers liquid financial instrument, and a further 102 million yuan in a fixed-income product tied to financial products and cash-type assets.
The company also invested 216 million yuan in a ten-year product that will be invested in financial products and cash-type assets.
The firm said the products will help "revitalize idle funds."